UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A study of cross-coverage calls

Journal of general internal medicine : JGIM, 1996-03, Vol.11 (3), p.189-189

1996

Volltextzugriff (PDF)

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Journal of clinical oncology, 2021-02, Vol.39 (4), p.273-284

2021

Volltextzugriff (PDF)

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

Journal of clinical oncology, 2019-06, Vol.37 (17), p.1460-1469

2019

Volltextzugriff (PDF)

Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3170-TPS3170

2022

Volltextzugriff (PDF)

Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3171-TPS3171

2022

Volltextzugriff (PDF)

Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3084-3084

2024

Volltextzugriff (PDF)

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS211-TPS211

2022

Volltextzugriff (PDF)

Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3513-3513

2021

Volltextzugriff (PDF)

Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3583-3583

2021

Volltextzugriff (PDF)

Global BRAF testing practices in metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e15523-e15523

2021

Volltextzugriff (PDF)

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant ( BRAF V600E ) metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS3619-TPS3619

2021

Volltextzugriff (PDF)

Global BRAF testing practices in metastatic colorectal cancer

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.128-128

2021

Volltextzugriff (PDF)

Immunology in Hodgkin's disease

Indian journal of cancer, 1972-12, Vol.9 (4), p.312

Gollerkeri, M P

1972

Volltextzugriff (PDF)

Immunity in cancer--a review

Indian journal of cancer, 1972-03, Vol.9 (1), p.92

Gollerkeri, M P

1972

Volltextzugriff (PDF)

Evaluation of general immune responsiveness in cancer patients

Indian journal of medical research (New Delhi, India : 1994), 1975-02, Vol.63 (2), p.315

1975

Volltextzugriff (PDF)

Evaluation of plasma lactate dehydrogenase (LDH) isoenzymes in cancer patients. I: qualitative and quantitative assessment in patients with chronic myeloid leukaemia and acute lymphatic leukemia

Indian journal of cancer, 1977-03, Vol.14 (1), p.42

1977

Volltextzugriff (PDF)

Search for tumor specific reactivity in human leukemias

Indian journal of cancer, 1973-09, Vol.10 (3), p.338

1973

Volltextzugriff (PDF)

Proliferation kinetics of granulocyte precursors in the bone-marrow of normal and chronic myeloid leukaemia patients

Indian journal of cancer, 1976-09, Vol.13 (3), p.272

1976

Volltextzugriff (PDF)

Evaluation of an 'in vitro' sensitivity test for human leukemic cells

Indian journal of cancer, 1975-09, Vol.12 (3), p.302

1975

Volltextzugriff (PDF)

Agglutinating and cytotoxic properties of anti-leukemic sera specific against human leukemic cells, produced in rabbits

Indian journal of cancer, 1972-09, Vol.9 (3), p.189

1972

Volltextzugriff (PDF)

Studies on the use of chemically tagged normal white blood cells as antigens for producing specific immune response against human leukemic cells

Indian journal of cancer, 1972-06, Vol.9 (2), p.101

1972

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(11)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Kollektion

Journals@Ovid
(21)
EZB Electronic Journals Library
(20)
Ingenta E-Journals
(20)
MEDLINE
(12)
Single Journals
(12)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(1)
Wiley Online Library Journals Frontfile Complete
(1)
SpringerLink Journals - AutoHoldings
(1)

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

A study of cross-coverage calls

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors

Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL)

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC)

Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study

Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC)

Global BRAF testing practices in metastatic colorectal cancer (mCRC)

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant ( BRAF V600E ) metastatic colorectal cancer (mCRC)

Global BRAF testing practices in metastatic colorectal cancer

Immunology in Hodgkin's disease

Immunity in cancer--a review

Evaluation of general immune responsiveness in cancer patients

Evaluation of plasma lactate dehydrogenase (LDH) isoenzymes in cancer patients. I: qualitative and quantitative assessment in patients with chronic myeloid leukaemia and acute lymphatic leukemia

Search for tumor specific reactivity in human leukemias

Proliferation kinetics of granulocyte precursors in the bone-marrow of normal and chronic myeloid leukaemia patients

Evaluation of an 'in vitro' sensitivity test for human leukemic cells

Agglutinating and cytotoxic properties of anti-leukemic sera specific against human leukemic cells, produced in rabbits

Studies on the use of chemically tagged normal white blood cells as antigens for producing specific immune response against human leukemic cells

Aktive Filter

Suchergebnisse filtern